0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global EGFR Inhibitor Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-0X15206
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global EGFR Inhibitor Market Research Report 2023
BUY CHAPTERS

Global EGFR Inhibitor Market Research Report 2025

Code: QYRE-Auto-0X15206
Report
May 2025
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

EGFR Inhibitor Market

The global market for EGFR Inhibitor was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for EGFR Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for EGFR Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of EGFR Inhibitor include AstraZeneca, Roche, Boehringer-Ingelheim, Pfizer, Mylan, Genvio Pharma, Alice, Teva Pharmaceuticals, Blueprint Medicines, Biotherapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for EGFR Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding EGFR Inhibitor.
The EGFR Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global EGFR Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the EGFR Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of EGFR Inhibitor Market Report

Report Metric Details
Report Name EGFR Inhibitor Market
Segment by Type
  • First Generation
  • Second Generation
  • Three Generations
  • Four Generations
Segment by Application
  • Healthcare
  • Experimental Use
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Roche, Boehringer-Ingelheim, Pfizer, Mylan, Genvio Pharma, Alice, Teva Pharmaceuticals, Blueprint Medicines, Biotherapeutics, Junshi Biosciences, Cttq, Betta Pharmaceuticals, Qilu Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of EGFR Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of EGFR Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the EGFR Inhibitor Market report?

Ans: The main players in the EGFR Inhibitor Market are AstraZeneca, Roche, Boehringer-Ingelheim, Pfizer, Mylan, Genvio Pharma, Alice, Teva Pharmaceuticals, Blueprint Medicines, Biotherapeutics, Junshi Biosciences, Cttq, Betta Pharmaceuticals, Qilu Pharmaceutical

What are the Application segmentation covered in the EGFR Inhibitor Market report?

Ans: The Applications covered in the EGFR Inhibitor Market report are Healthcare, Experimental Use, Other

What are the Type segmentation covered in the EGFR Inhibitor Market report?

Ans: The Types covered in the EGFR Inhibitor Market report are First Generation, Second Generation, Three Generations, Four Generations

Recommended Reports

Inhibitor Therapeutics

Cancer Targeted Drugs

Anti-VEGF & Angiogenesis

1 EGFR Inhibitor Market Overview
1.1 Product Definition
1.2 EGFR Inhibitor by Type
1.2.1 Global EGFR Inhibitor Market Value Comparison by Type (2024 VS 2031)
1.2.2 First Generation
1.2.3 Second Generation
1.2.4 Three Generations
1.2.5 Four Generations
1.3 EGFR Inhibitor by Application
1.3.1 Global EGFR Inhibitor Market Value by Application (2024 VS 2031)
1.3.2 Healthcare
1.3.3 Experimental Use
1.3.4 Other
1.4 Global EGFR Inhibitor Market Size Estimates and Forecasts
1.4.1 Global EGFR Inhibitor Revenue 2020-2031
1.4.2 Global EGFR Inhibitor Sales 2020-2031
1.4.3 Global EGFR Inhibitor Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 EGFR Inhibitor Market Competition by Manufacturers
2.1 Global EGFR Inhibitor Sales Market Share by Manufacturers (2020-2025)
2.2 Global EGFR Inhibitor Revenue Market Share by Manufacturers (2020-2025)
2.3 Global EGFR Inhibitor Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of EGFR Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of EGFR Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of EGFR Inhibitor, Product Type & Application
2.7 Global Key Manufacturers of EGFR Inhibitor, Date of Enter into This Industry
2.8 Global EGFR Inhibitor Market Competitive Situation and Trends
2.8.1 Global EGFR Inhibitor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest EGFR Inhibitor Players Market Share by Revenue
2.8.3 Global EGFR Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global EGFR Inhibitor Market Scenario by Region
3.1 Global EGFR Inhibitor Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global EGFR Inhibitor Sales by Region: 2020-2031
3.2.1 Global EGFR Inhibitor Sales by Region: 2020-2025
3.2.2 Global EGFR Inhibitor Sales by Region: 2026-2031
3.3 Global EGFR Inhibitor Revenue by Region: 2020-2031
3.3.1 Global EGFR Inhibitor Revenue by Region: 2020-2025
3.3.2 Global EGFR Inhibitor Revenue by Region: 2026-2031
3.4 North America EGFR Inhibitor Market Facts & Figures by Country
3.4.1 North America EGFR Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America EGFR Inhibitor Sales by Country (2020-2031)
3.4.3 North America EGFR Inhibitor Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe EGFR Inhibitor Market Facts & Figures by Country
3.5.1 Europe EGFR Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe EGFR Inhibitor Sales by Country (2020-2031)
3.5.3 Europe EGFR Inhibitor Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific EGFR Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific EGFR Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific EGFR Inhibitor Sales by Region (2020-2031)
3.6.3 Asia Pacific EGFR Inhibitor Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America EGFR Inhibitor Market Facts & Figures by Country
3.7.1 Latin America EGFR Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America EGFR Inhibitor Sales by Country (2020-2031)
3.7.3 Latin America EGFR Inhibitor Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa EGFR Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa EGFR Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa EGFR Inhibitor Sales by Country (2020-2031)
3.8.3 Middle East and Africa EGFR Inhibitor Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global EGFR Inhibitor Sales by Type (2020-2031)
4.1.1 Global EGFR Inhibitor Sales by Type (2020-2025)
4.1.2 Global EGFR Inhibitor Sales by Type (2026-2031)
4.1.3 Global EGFR Inhibitor Sales Market Share by Type (2020-2031)
4.2 Global EGFR Inhibitor Revenue by Type (2020-2031)
4.2.1 Global EGFR Inhibitor Revenue by Type (2020-2025)
4.2.2 Global EGFR Inhibitor Revenue by Type (2026-2031)
4.2.3 Global EGFR Inhibitor Revenue Market Share by Type (2020-2031)
4.3 Global EGFR Inhibitor Price by Type (2020-2031)
5 Segment by Application
5.1 Global EGFR Inhibitor Sales by Application (2020-2031)
5.1.1 Global EGFR Inhibitor Sales by Application (2020-2025)
5.1.2 Global EGFR Inhibitor Sales by Application (2026-2031)
5.1.3 Global EGFR Inhibitor Sales Market Share by Application (2020-2031)
5.2 Global EGFR Inhibitor Revenue by Application (2020-2031)
5.2.1 Global EGFR Inhibitor Revenue by Application (2020-2025)
5.2.2 Global EGFR Inhibitor Revenue by Application (2026-2031)
5.2.3 Global EGFR Inhibitor Revenue Market Share by Application (2020-2031)
5.3 Global EGFR Inhibitor Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca EGFR Inhibitor Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche EGFR Inhibitor Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Boehringer-Ingelheim
6.3.1 Boehringer-Ingelheim Company Information
6.3.2 Boehringer-Ingelheim Description and Business Overview
6.3.3 Boehringer-Ingelheim EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Boehringer-Ingelheim EGFR Inhibitor Product Portfolio
6.3.5 Boehringer-Ingelheim Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer EGFR Inhibitor Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Mylan
6.5.1 Mylan Company Information
6.5.2 Mylan Description and Business Overview
6.5.3 Mylan EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Mylan EGFR Inhibitor Product Portfolio
6.5.5 Mylan Recent Developments/Updates
6.6 Genvio Pharma
6.6.1 Genvio Pharma Company Information
6.6.2 Genvio Pharma Description and Business Overview
6.6.3 Genvio Pharma EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Genvio Pharma EGFR Inhibitor Product Portfolio
6.6.5 Genvio Pharma Recent Developments/Updates
6.7 Alice
6.7.1 Alice Company Information
6.7.2 Alice Description and Business Overview
6.7.3 Alice EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Alice EGFR Inhibitor Product Portfolio
6.7.5 Alice Recent Developments/Updates
6.8 Teva Pharmaceuticals
6.8.1 Teva Pharmaceuticals Company Information
6.8.2 Teva Pharmaceuticals Description and Business Overview
6.8.3 Teva Pharmaceuticals EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Teva Pharmaceuticals EGFR Inhibitor Product Portfolio
6.8.5 Teva Pharmaceuticals Recent Developments/Updates
6.9 Blueprint Medicines
6.9.1 Blueprint Medicines Company Information
6.9.2 Blueprint Medicines Description and Business Overview
6.9.3 Blueprint Medicines EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Blueprint Medicines EGFR Inhibitor Product Portfolio
6.9.5 Blueprint Medicines Recent Developments/Updates
6.10 Biotherapeutics
6.10.1 Biotherapeutics Company Information
6.10.2 Biotherapeutics Description and Business Overview
6.10.3 Biotherapeutics EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Biotherapeutics EGFR Inhibitor Product Portfolio
6.10.5 Biotherapeutics Recent Developments/Updates
6.11 Junshi Biosciences
6.11.1 Junshi Biosciences Company Information
6.11.2 Junshi Biosciences Description and Business Overview
6.11.3 Junshi Biosciences EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Junshi Biosciences EGFR Inhibitor Product Portfolio
6.11.5 Junshi Biosciences Recent Developments/Updates
6.12 Cttq
6.12.1 Cttq Company Information
6.12.2 Cttq Description and Business Overview
6.12.3 Cttq EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Cttq EGFR Inhibitor Product Portfolio
6.12.5 Cttq Recent Developments/Updates
6.13 Betta Pharmaceuticals
6.13.1 Betta Pharmaceuticals Company Information
6.13.2 Betta Pharmaceuticals Description and Business Overview
6.13.3 Betta Pharmaceuticals EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Betta Pharmaceuticals EGFR Inhibitor Product Portfolio
6.13.5 Betta Pharmaceuticals Recent Developments/Updates
6.14 Qilu Pharmaceutical
6.14.1 Qilu Pharmaceutical Company Information
6.14.2 Qilu Pharmaceutical Description and Business Overview
6.14.3 Qilu Pharmaceutical EGFR Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Qilu Pharmaceutical EGFR Inhibitor Product Portfolio
6.14.5 Qilu Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 EGFR Inhibitor Industry Chain Analysis
7.2 EGFR Inhibitor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 EGFR Inhibitor Production Mode & Process Analysis
7.4 EGFR Inhibitor Sales and Marketing
7.4.1 EGFR Inhibitor Sales Channels
7.4.2 EGFR Inhibitor Distributors
7.5 EGFR Inhibitor Customer Analysis
8 EGFR Inhibitor Market Dynamics
8.1 EGFR Inhibitor Industry Trends
8.2 EGFR Inhibitor Market Drivers
8.3 EGFR Inhibitor Market Challenges
8.4 EGFR Inhibitor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global EGFR Inhibitor Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global EGFR Inhibitor Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global EGFR Inhibitor Market Competitive Situation by Manufacturers in 2024
 Table 4. Global EGFR Inhibitor Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global EGFR Inhibitor Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global EGFR Inhibitor Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global EGFR Inhibitor Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market EGFR Inhibitor Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of EGFR Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of EGFR Inhibitor, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of EGFR Inhibitor, Product Type & Application
 Table 12. Global Key Manufacturers of EGFR Inhibitor, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global EGFR Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in EGFR Inhibitor as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global EGFR Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global EGFR Inhibitor Sales by Region (2020-2025) & (K Units)
 Table 18. Global EGFR Inhibitor Sales Market Share by Region (2020-2025)
 Table 19. Global EGFR Inhibitor Sales by Region (2026-2031) & (K Units)
 Table 20. Global EGFR Inhibitor Sales Market Share by Region (2026-2031)
 Table 21. Global EGFR Inhibitor Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global EGFR Inhibitor Revenue Market Share by Region (2020-2025)
 Table 23. Global EGFR Inhibitor Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global EGFR Inhibitor Revenue Market Share by Region (2026-2031)
 Table 25. North America EGFR Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America EGFR Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 27. North America EGFR Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 28. North America EGFR Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America EGFR Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe EGFR Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe EGFR Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 32. Europe EGFR Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 33. Europe EGFR Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe EGFR Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific EGFR Inhibitor Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific EGFR Inhibitor Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific EGFR Inhibitor Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific EGFR Inhibitor Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific EGFR Inhibitor Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America EGFR Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America EGFR Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America EGFR Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America EGFR Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America EGFR Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa EGFR Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa EGFR Inhibitor Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa EGFR Inhibitor Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa EGFR Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa EGFR Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global EGFR Inhibitor Sales (K Units) by Type (2020-2025)
 Table 51. Global EGFR Inhibitor Sales (K Units) by Type (2026-2031)
 Table 52. Global EGFR Inhibitor Sales Market Share by Type (2020-2025)
 Table 53. Global EGFR Inhibitor Sales Market Share by Type (2026-2031)
 Table 54. Global EGFR Inhibitor Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global EGFR Inhibitor Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global EGFR Inhibitor Revenue Market Share by Type (2020-2025)
 Table 57. Global EGFR Inhibitor Revenue Market Share by Type (2026-2031)
 Table 58. Global EGFR Inhibitor Price (US$/Unit) by Type (2020-2025)
 Table 59. Global EGFR Inhibitor Price (US$/Unit) by Type (2026-2031)
 Table 60. Global EGFR Inhibitor Sales (K Units) by Application (2020-2025)
 Table 61. Global EGFR Inhibitor Sales (K Units) by Application (2026-2031)
 Table 62. Global EGFR Inhibitor Sales Market Share by Application (2020-2025)
 Table 63. Global EGFR Inhibitor Sales Market Share by Application (2026-2031)
 Table 64. Global EGFR Inhibitor Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global EGFR Inhibitor Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global EGFR Inhibitor Revenue Market Share by Application (2020-2025)
 Table 67. Global EGFR Inhibitor Revenue Market Share by Application (2026-2031)
 Table 68. Global EGFR Inhibitor Price (US$/Unit) by Application (2020-2025)
 Table 69. Global EGFR Inhibitor Price (US$/Unit) by Application (2026-2031)
 Table 70. AstraZeneca Company Information
 Table 71. AstraZeneca Description and Business Overview
 Table 72. AstraZeneca EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AstraZeneca EGFR Inhibitor Product
 Table 74. AstraZeneca Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Roche EGFR Inhibitor Product
 Table 79. Roche Recent Developments/Updates
 Table 80. Boehringer-Ingelheim Company Information
 Table 81. Boehringer-Ingelheim Description and Business Overview
 Table 82. Boehringer-Ingelheim EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Boehringer-Ingelheim EGFR Inhibitor Product
 Table 84. Boehringer-Ingelheim Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Pfizer EGFR Inhibitor Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Mylan Company Information
 Table 91. Mylan Description and Business Overview
 Table 92. Mylan EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Mylan EGFR Inhibitor Product
 Table 94. Mylan Recent Developments/Updates
 Table 95. Genvio Pharma Company Information
 Table 96. Genvio Pharma Description and Business Overview
 Table 97. Genvio Pharma EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Genvio Pharma EGFR Inhibitor Product
 Table 99. Genvio Pharma Recent Developments/Updates
 Table 100. Alice Company Information
 Table 101. Alice Description and Business Overview
 Table 102. Alice EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Alice EGFR Inhibitor Product
 Table 104. Alice Recent Developments/Updates
 Table 105. Teva Pharmaceuticals Company Information
 Table 106. Teva Pharmaceuticals Description and Business Overview
 Table 107. Teva Pharmaceuticals EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Teva Pharmaceuticals EGFR Inhibitor Product
 Table 109. Teva Pharmaceuticals Recent Developments/Updates
 Table 110. Blueprint Medicines Company Information
 Table 111. Blueprint Medicines Description and Business Overview
 Table 112. Blueprint Medicines EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Blueprint Medicines EGFR Inhibitor Product
 Table 114. Blueprint Medicines Recent Developments/Updates
 Table 115. Biotherapeutics Company Information
 Table 116. Biotherapeutics Description and Business Overview
 Table 117. Biotherapeutics EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Biotherapeutics EGFR Inhibitor Product
 Table 119. Biotherapeutics Recent Developments/Updates
 Table 120. Junshi Biosciences Company Information
 Table 121. Junshi Biosciences Description and Business Overview
 Table 122. Junshi Biosciences EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Junshi Biosciences EGFR Inhibitor Product
 Table 124. Junshi Biosciences Recent Developments/Updates
 Table 125. Cttq Company Information
 Table 126. Cttq Description and Business Overview
 Table 127. Cttq EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Cttq EGFR Inhibitor Product
 Table 129. Cttq Recent Developments/Updates
 Table 130. Betta Pharmaceuticals Company Information
 Table 131. Betta Pharmaceuticals Description and Business Overview
 Table 132. Betta Pharmaceuticals EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Betta Pharmaceuticals EGFR Inhibitor Product
 Table 134. Betta Pharmaceuticals Recent Developments/Updates
 Table 135. Qilu Pharmaceutical Company Information
 Table 136. Qilu Pharmaceutical Description and Business Overview
 Table 137. Qilu Pharmaceutical EGFR Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Qilu Pharmaceutical EGFR Inhibitor Product
 Table 139. Qilu Pharmaceutical Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. EGFR Inhibitor Distributors List
 Table 143. EGFR Inhibitor Customers List
 Table 144. EGFR Inhibitor Market Trends
 Table 145. EGFR Inhibitor Market Drivers
 Table 146. EGFR Inhibitor Market Challenges
 Table 147. EGFR Inhibitor Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of EGFR Inhibitor
 Figure 2. Global EGFR Inhibitor Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global EGFR Inhibitor Market Share by Type: 2024 & 2031
 Figure 4. First Generation Product Picture
 Figure 5. Second Generation Product Picture
 Figure 6. Three Generations Product Picture
 Figure 7. Four Generations Product Picture
 Figure 8. Global EGFR Inhibitor Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global EGFR Inhibitor Market Share by Application: 2024 & 2031
 Figure 10. Healthcare
 Figure 11. Experimental Use
 Figure 12. Other
 Figure 13. Global EGFR Inhibitor Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global EGFR Inhibitor Market Size (2020-2031) & (US$ Million)
 Figure 15. Global EGFR Inhibitor Sales (2020-2031) & (K Units)
 Figure 16. Global EGFR Inhibitor Average Price (US$/Unit) & (2020-2031)
 Figure 17. EGFR Inhibitor Report Years Considered
 Figure 18. EGFR Inhibitor Sales Share by Manufacturers in 2024
 Figure 19. Global EGFR Inhibitor Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest EGFR Inhibitor Players: Market Share by Revenue in EGFR Inhibitor in 2024
 Figure 21. EGFR Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global EGFR Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America EGFR Inhibitor Sales Market Share by Country (2020-2031)
 Figure 24. North America EGFR Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 25. United States EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe EGFR Inhibitor Sales Market Share by Country (2020-2031)
 Figure 28. Europe EGFR Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 29. Germany EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific EGFR Inhibitor Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific EGFR Inhibitor Revenue Market Share by Region (2020-2031)
 Figure 36. China EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America EGFR Inhibitor Sales Market Share by Country (2020-2031)
 Figure 44. Latin America EGFR Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa EGFR Inhibitor Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa EGFR Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE EGFR Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of EGFR Inhibitor by Type (2020-2031)
 Figure 54. Global Revenue Market Share of EGFR Inhibitor by Type (2020-2031)
 Figure 55. Global EGFR Inhibitor Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of EGFR Inhibitor by Application (2020-2031)
 Figure 57. Global Revenue Market Share of EGFR Inhibitor by Application (2020-2031)
 Figure 58. Global EGFR Inhibitor Price (US$/Unit) by Application (2020-2031)
 Figure 59. EGFR Inhibitor Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart